The role of angiogenesis in the physiopathology of renal cell carcinoma is fundamental.
Strategies targeting angiogenesis have been developed including VEGF and VEGFR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC), in first and second line. Pazopanib is an angiogenesis inhibitor targeting VEGF receptor, PDGF receptor and c-KIT receptor. This treatment is a treatment option recommended for patients with mRCC, would be in first line or after cytokines failure. Pazopanib has been recently approved for patients with metastatic soft tissue sarcoma, after failure of at least one line of chemotherapy.
Written by:
Brotelle T, Bay JO. Are you the author?
Centre Jean-Perrin, Département d'oncologie médicale, 58, rue Montalembert, 63011 Clermont-Ferrand cedex 01, France.
Reference: Bull Cancer. 2014 Jun;101(6):641-6.
doi: 10.1684/bdc.2014.1981
PubMed Abstract
PMID: 24977453
Article in French.
UroToday.com Renal Cancer Section
